Discussion : Key aspects include:
• Detailed slit-lamp examination
• Corneal scraping and microbiological workup
• Anterior segment optical coherence tomography (AS-OCT)
• Assessment of scleral and intraocular involvement
• Evaluation of systemic autoimmune disease when indicated
Timing of surgery is crucial. Early intervention is preferred in rapidly progressive infections or imminent perforation.
Outcomes of Therapeutic Keratoplasty14
• Anatomical Success
Defined as maintenance of globe integrity, anatomical success rates range from 75–90% depending on etiology.
Therapeutic Success
Complete eradication of infection is achieved in approximately 70–85% of cases.
• Visual Outcomes
Visual outcomes are typically limited due to:
Graft scarring
Irregular astigmatism
Secondary glaucoma
Graft failure
Most patients require secondary optical keratoplasty for visual rehabilitation.
• Postoperative Management15
Postoperative therapy is guided by the underlying pathology:
Tailored antimicrobial therapy
Delayed introduction of corticosteroids (especially in fungal keratitis)
Lubrication and epithelial healing support
Monitoring intraocular pressure
Management of immune-mediated graft reactions
Close follow-up is essential in the early postoperative phase.
• Complications of Therapeutic Keratoplasty. Common complications include:9
Graft rejection
Recurrent infection
Secondary glaucoma
Graft failure
Persistent epithelial defects
Endophthalmitis (rare but serious)
• Risk is higher in:10
Actively infected eyes
Large grafts (>9 mm)
Patients with autoimmune disorders
• Therapeutic Keratoplasty in Fungal Keratitis
Fungal keratitis remains the commonest indication for TKP in tropical countries. Delayed response to antifungals and deep stromal invasion necessitate early surgical intervention. TKP significantly improves anatomical survival but visual prognosis remains guarded.
• Pediatric Therapeutic Keratoplasty
Outcomes in children are poorer due to:
Aggressive infections
Higher rejection rates
Amblyopia risk
Poor postoperative compliance
Despite this, TKP is often vision- and globe-saving.
• Donor Tissue Challenges4
Key issues include:
Scarcity of good-quality donor corneas
Use of glycerol-preserved corneas in emergencies
Increased risk of graft failure with poor-quality tissue
Advances in tissue banking and preservation techniques may improve availability.
• Advances in Therapeutic Keratoplasty7
Integration of lamellar keratoplasty
Use of amniotic membrane transplantation as a temporizing procedure
Femtosecond laser-assisted keratoplasty
Adjunctive intracameral and intrastromal antimicrobials
Role of collagen cross-linking as adjuvant therapy
• Role of Therapeutic Keratoplasty in the Era of Advanced Medical Therapy
Despite newer antifungals, antibiotics, and targeted drug delivery systems, drug resistance, delayed presentation, and poor penetration of drugs into deep stroma ensure that TKP remains indispensable. It also serves a dual role by providing tissue for histopathological diagnosis.
• Prognostic Factors3
Better outcomes are associated with:
Early surgery
Smaller graft size
Absence of scleral extension
Good postoperative compliance
Prompt control of infection
Poor prognosis factors include:
Large perforations
Panophthalmitis
Severe autoimmune disease
Multiple prior grafts
• Future Directions
Future research is focused on:
Bioengineered corneas
Artificial corneal substitutes (keratoprosthesis)
Improved antifungal drug delivery
Regenerative therapies using stem cells
Automated lamellar dissection techniques
Conclusion : Therapeutic keratoplasty continues to be a cornerstone in the management of severe corneal disease. Although originally designed as a globe-salvaging procedure, evolving surgical techniques and improved postoperative care have expanded its role toward functional rehabilitation as well. Early decision-making, appropriate patient selection, and meticulous postoperative management remain the key determinants of success. As medical therapy and surgical technology advance, TKP will continue to evolve but will remain an irreplaceable tool in corneal surgery.
References :
1. Sharma N, et al. Evaluation of therapeutic keratoplasty in infectious keratitis. Cornea. 2013;32(8):1030–1036.
2. Dua HS, et al. Clinical outcomes of therapeutic keratoplasty. Eye. 2009;23:539–546.
3. Panda A, et al. Tectonic keratoplasty in corneal melts. Indian J Ophthalmol. 2015;63:217–222.
4. Xie L, et al. Therapeutic penetrating keratoplasty in severe fungal keratitis. Ophthalmology. 2002;109:1216–1223.
5. Srinivasan M. Fungal keratitis. Curr Opin Ophthalmol. 2004;15(4):321–327.
6. Thomas PA, Kaliamurthy J. Mycotic keratitis: Epidemiology and diagnosis. Clin Microbiol Rev. 2013;26:557–580.
7. Green M, et al. Recurrent infection after therapeutic keratoplasty. Am J Ophthalmol. 2010;150:76–82.
8. Reinhart WJ, et al. Visual outcomes after therapeutic keratoplasty. Cornea. 2011;30:109–115.
9. Vajpayee RB, et al. Lamellar keratoplasty in infectious keratitis. Surv Ophthalmol. 2007;52:245–259.
10. Sarnicola V, et al. Deep anterior lamellar keratoplasty: Indications and complications. Eye. 2012;26:124–128.
11. Jones DB. Decision-making in keratoplasty for infection. Trans Am Ophthalmol Soc. 1981;79:583–636.
12. Wagoner MD. Etiology of infectious keratitis. Am J Ophthalmol. 1997;123:349–357.
13. Sharma A, Kaur R. Graft survival after therapeutic keratoplasty. Cornea. 2020;39:875–882.
14. Randleman JB, et al. Risk factors for graft failure following therapeutic PK. Ophthalmology. 2003;110:1667–1674.
15. Tan DT, et al. Corneal transplantation. Lancet. 2012;379:1749–1761.